Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASOX Adjuvant Therapy for Pancreatic Cancer
NCT06361316Recruiting
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of irinotecan liposome in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Disease Free Survival at 21.6 months. Started Apr 2024; status: recruiting.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06361316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361316.